Neutralizing antibody production against Rebif® and ReciGen® in Relapsing-Remitting Multiple Sclerosis (RRMS) patients and its association with patient's disability

Neutralizing antibody production against Rebif® and ReciGen® in Relapsing-Remitting Multiple Sclerosis (RRMS) patients and its association with patient's disability


چاپ صفحه
پژوهان
صفحه نخست سامانه
چکیده مقاله
چکیده مقاله
نویسندگان
نویسندگان
دانلود مقاله
دانلود مقاله
علوم پزشکی اراک
علوم پزشکی اراک

نویسندگان: قاسم مسیبی

کلمات کلیدی: KEYWORDS: Interferon beta; Neutralizing antibody; RRMS; Rebif®; ReciGen®

نشریه: International Immunopharmacology, 62,,109 - 113,2018

اطلاعات کلی مقاله
hide/show

کد مقاله 4426
عنوان فارسی مقاله Neutralizing antibody production against Rebif® and ReciGen® in Relapsing-Remitting Multiple Sclerosis (RRMS) patients and its association with patient's disability
عنوان لاتین مقاله Neutralizing antibody production against Rebif® and ReciGen® in Relapsing-Remitting Multiple Sclerosis (RRMS) patients and its association with patient's disability
نوع مقاله بر حسب نگارش پژوهشی اصیل
مقاله برحسب نمایه ISI
IF 3.118
عنوان نشریه International Immunopharmacology
نوع نشریه علمی پژوهشی
شماره نشریه 62
دوره 62
صفحه شروع و پایان در نشریه 109 - 113
سال انتشار/ ارائه شمسی 1397
سال انتشار/ارائه میلادی 2018
آدرس لینک مقاله/ همایش در شبکه اینترنت www.sciencedirect.com/science/article/pii/S1567576918302832
ISSN 1567-5769
DOI
آدرس علمی (Affiliation) نویسنده متقاضی Molecular and Medicine Research Center, Arak University of Medical Sciences

چکیده مقاله
hide/show

عنوان متن
چکیده انگلیسیAbstract INTRODUCTION: Human recombinant interferon beta (IFN-β) is one of the first line treatments for Relapsing-Remitting Multiple Sclerosis (RRMS). However, the production of neutralizing antibodies (NAb) can impair its function. The aim of this study was to investigate the production of neutralizing antibodies against Rebif® and ReciGen® (two brands of IFN-β-1a) and to evaluate its correlation with Expanded Disability Status Scale (EDSS). MATERIALS AND METHODS: Serum samples of 71 RRMS patients (34 in ReciGen®, 37 in Rebif® group) were collected. Neutralizing antibody was measured by Myxo-virus resistance protein A (MxA) assay using A549 cell line. The MxA concentration was measured by enzyme-linked immunosorbent assay (ELISA) kit. RESULTS: The median period of treatment with IFN-β-1a was 18 months in ReciGen® and 24 months in Rebif® arms. The percentage of patients with positive titer of neutralizing antibody (NAb+) had no statistically significant difference between groups (P = 0.6). In both ReciGen® and Rebif® groups, the increase in EDSS score was significantly higher in NAb+ patients compared to NAb- patients (p ≤ 0.05). The duration of using ReciGen® or Rebif® for >24 months was influential in the NAb positivity (OR = 3.78). CONCLUSION: Receiving interferon beta-1a for >24 months is correlated with higher possibility of NAb production. The type of IFN-β used in the study had no significant impact on NAb positivity. In addition, both groups had comparable EDSS score changes, and NAb status of patients was correlated with their EDSS score
چکیده
کلمات کلیدیKEYWORDS: Interferon beta; Neutralizing antibody; RRMS; Rebif®; ReciGen®
نام فایل عنوان پیوست تاریخ درج فایل اندازه فایل دانلود

نویسندگان
hide/show

نویسنده نفر چندم مقاله
قاسم مسیبیپنجم

لینک دانلود مقاله
hide/show

نام فایل عنوان پیوست تاریخ درج فایل اندازه فایل دانلود
Neutralizing antibody production against Rebif and ReciGen in MS patients.pdf 1397/04/19405220دانلود
dr mosayebi.pdfتصویر نمایه مقاله در ISI1397/07/28245163دانلود